Financial Performance - Core revenue (tissue and hygiene products) decreased by 3.1% to RMB 10.5 billion in 1H2025, compared to RMB 10.8 billion in 1H2024[9] - Profit attributable to shareholders decreased by 2.6% to RMB 1.37 billion in 1H2025, compared to RMB 1.41 billion in 1H2024[9] - Overall revenue slightly decreased by 0.2% to RMB 11,808.232 million in 1H2025, from RMB 11,835.893 million in 1H2024[15] - Basic earnings per share (EPS) decreased by 2.3% to RMB 1.206 in 1H2025, from RMB 1.234 in 1H2024[15] - Interim dividend per share remained unchanged at RMB 0.70[15] Business Segments - Tissue paper revenue increased by 3.2% to RMB 7,173.7 million in 1H2025, compared to RMB 6,950.578 million in 1H2024[18] - Hygiene products revenue decreased by 14.4% to RMB 3,303.839 million in 1H2025, compared to RMB 3,858.570 million in 1H2024[18] - Other revenue increased by 29.6% to RMB 1,330.693 million in 1H2025, compared to RMB 1,026.745 million in 1H2024[18] - Tissue paper sales in e-commerce and new retail channels rose significantly by 15.1%, accounting for nearly 40.9% of overall tissue sales[44] Financial Position - Net cash increased to RMB 6.4 billion in 1H2025, from RMB 5.4 billion in 1H2024[9] - Gearing ratio decreased to 77.5% in 1H2025, from 99.1% in 1H2024[9] - E-commerce and new retail channels sales Up 7.9%, to over RMB 4.06 billion[54] ESG - The company maintained a BBB rating from MSCI ESG Rating[11, 58]